Flemming Ørnskov
Flemming Ørnskov (born 1957/58) is a Danish businessman. He is the chief executive officer (CEO) of Galderma[2] and has previously been the CEO of Shire plc, a FTSE 100 speciality biopharmaceutical company since 30 April 2013, succeeding Angus Russell.[3] He previously worked for Bayer, Bausch & Lomb and Novartis.[2]
Flemming Ørnskov | |
|---|---|
| Born | 1957/1958 (age 61–62)[1] |
| Nationality | Danish |
| Alma mater | University of Copenhagen INSEAD Harvard University |
| Occupation | CEO, Shire plc |
Ørnskov received his MD from the University of Copenhagen, followed by an MBA from INSEAD, and a Master of Public Health (MPH) from Harvard University.[1]
References
- "Executive Profile: Flemming Ornskov". Bloomberg. Retrieved 4 September 2017.
- Liu, Angus (October 8, 2019). "Ex-Shire CEO Flemming Ornskov emerges as Galderma CEO after $10B Nestlé spinout". Fiercepharma.
- "Shire chief finds right prescription for growth". The Telegraph. Retrieved 20 March 2014.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.